Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

ABSTRACT: This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

DISEASE(S): Neuroendocrine Tumors,Thyroid Neoplasms,Sarcomas,Malignant Solid Tumor,Colorectal Cancer,Head And Neck Neoplasms,Neoplasms,Brain Neoplasms,Ovarian Cancer,Primary Brain Tumors,Adult Solid Tumor,Lymphoma, Large-cell, Anaplastic,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Ovarian Neoplasms,Renal Cell Carcinoma,Pancreatic Neoplasms,Cholangiocarcinoma,Salivary Gland Neoplasms,Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk1/2/3, Ros1, or Alk Gene Rearrangements,Sarcoma,Melanoma,Papillary Thyroid Cancer,Pancreatic Cancer,Breast Cancer,Thyroid Cancer, Papillary,Non-small Cell Lung Cancer,Salivary Gland Cancers,Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk1/2/3, Ros1,or Alk Gene Rearrangements

PROVIDER: 2199524 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR